Literature DB >> 12511821

A Treatment Algorithm for Attention Deficit Hyperactivity Disorder in Cocaine-Dependent Adults: A One-Year Private Practice Study with Long-Acting Stimulants, Fluoxetine, and Bupropion.

Ricardo Castaneda1, Norman Sussman, Robert Levy, Manuel Trujillo.   

Abstract

A subgroup of adults in private treatment for cocaine dependence in remission reported a therapeutic effect from cocaine during the initial phases of cocaine addiction and, also, met DSM-IV criteria for ADHD. We report evidence that study subjects probably medicated their ADHD symptoms with cocaine and describe a 1-year treatment algorithm featuring long-acting stimulants that was effective in the management of their ADHD and cocaine dependence. Nineteen stable patients in full remission from all substance dependence were entered into an open label, prospective, treatment trial for ADHD. The treatment schedule consisted of the progressive introduction-and discontinuation of ineffective medication-of each of several medications in the following order: fluoxetine, bupropion, pemoline, sustained-release methylphenidate, dextroamphetamine spansules, and methamphetamine gradumets. Treatment of ADHD was successful. Several treatment regimens, especially those including long-acting stimulants, alone or in combination with other agents, were highly effective. All but 1 of the 19 subjects had a fully effective response for at least 1 full year. Mean UTAH scale scores were 7.4 before any medications were administered and 1.6 at the end of the study. Treatment proved successful in suppressing ADHD symptoms, with minimal cocaine slips or side effects.

Entities:  

Year:  1999        PMID: 12511821     DOI: 10.1080/08897079909511394

Source DB:  PubMed          Journal:  Subst Abus        ISSN: 0889-7077            Impact factor:   3.716


  6 in total

1.  Open-label pilot study of bupropion plus bromocriptine for treatment of cocaine dependence.

Authors:  Ivan D Montoya; Kenzie L Preston; Richard Rothman; David A Gorelick
Journal:  Am J Drug Alcohol Abuse       Date:  2002       Impact factor: 3.829

Review 2.  A review of OROS methylphenidate (Concerta(®)) in the treatment of attention-deficit/hyperactivity disorder.

Authors:  Martin A Katzman; Tia Sternat
Journal:  CNS Drugs       Date:  2014-11       Impact factor: 5.749

3.  Lisdexamfetamine dimesylate for the treatment of attention deficit hyperactivity disorder in adults with a history of depression or history of substance use disorder.

Authors:  Scott H Kollins; Sharon Youcha; Robert Lasser; Michael E Thase
Journal:  Innov Clin Neurosci       Date:  2011-02

Review 4.  Pharmacological and clinical dilemmas of prescribing in co-morbid adult attention-deficit/hyperactivity disorder and addiction.

Authors:  José Pérez de los Cobos; Núria Siñol; Víctor Pérez; Joan Trujols
Journal:  Br J Clin Pharmacol       Date:  2014-02       Impact factor: 4.335

5.  Amphetamine and mCPP effects on dopamine and serotonin striatal in vivo microdialysates in an animal model of hyperactivity.

Authors:  Przemyslaw Nowak; Aleksandra Bortel; Joanna Dabrowska; Joanna Oswiecimska; Marzena Drosik; Adam Kwiecinski; Józef Opara; Richard M Kostrzewa; Ryszard Brus
Journal:  Neurotox Res       Date:  2007-02       Impact factor: 3.911

Review 6.  Clinical potential of methylphenidate in the treatment of cocaine addiction: a review of the current evidence.

Authors:  Kenneth M Dürsteler; Eva-Maria Berger; Johannes Strasser; Carlo Caflisch; Jochen Mutschler; Marcus Herdener; Marc Vogel
Journal:  Subst Abuse Rehabil       Date:  2015-06-17
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.